Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Collagen dynamics in the breast cancer tumor microenvironment and therapeutic perspectives

Wu D., Liu L., Jiang Y., Qian Z., You Y., Ning X.

Clinical Trial on Immune Modulation, published in Discov Oncol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Discov Oncol (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41315075
PMCID
PMC12770041
DOI
10.1007/s12672-025-04182-8

Abstract (original English)

Breast Cancer (BC) remains one of the most prevalent malignancies among women globally, with its pathogenesis and clinical progression being profoundly regulated by the tumor microenvironment (TME). Collagen, the most abundant extracellular matrix (ECM) component, plays multifaceted roles in shaping the TME of BC. Aberrant cllagen deposition, crosslinking, and remodeling alter tissue stiffness and architecture, driving tumor initiation, growth, invasion, and metastasis through integrin and discoidin domain receptor-mediated mechanosignaling, growth factor regulation, and metabolic reprogramming. Collagen rich stroma also acts as a physical and biochemical barrier that restricts T cell infiltration, promotes macrophage polarization, and impairs natural killer cell (NK) cytotoxicity, thereby facilitating immune evasion and therapeutic resistance. Specific collagen isoforms, including types I, III, V, VI, X, and XI, exhibit context-dependent tumor promoting or tumor restraining effects, underscoring the complexity of roles. Recent advances in targeting collagen biology, such as enzymatic degradation, inhibition of crosslinking enzymes, blockade of collagen receptors, and immune modulation strategies demonstrates promising preclinical results, with several approaches progressing to clinical trials. Future perspectives emphasize the integration of collagen targeting therapies with i

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research